Patient characteristics
Patient | Age | Sex | Baseline | Follow up | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NYHA | CAD | CABG | EF (%) | WMSI | DS | PET viable | DE viable | NYHA | EF (%) | WMSI | ||||
1 | 45 | M | III1-150 | LAD, CX, RCA | 3 | 32 | 1.8 | 9 | 9 | 9 | I | 54 | 1.1 | |
2 | 49 | M | IV | LAD, CX, RCA | 4 | 17 | 2.3 | 14 | 14 | 9 | I | 24 | 1.6 | |
3 | 41 | F | III1-150 | LAD, CX, RCA | 2 | 37 | 1.8 | 12 | 5 | 9 | I | 29 | 1.7 | |
4 | 57 | M | III | LAD, CX | 2 | 23 | 2.3 | 15 | 13 | 8 | I | 38 | 1.5 | |
5 | 54 | M | III | LAD, CX, RCA | 3 | 30 | 1.8 | 10 | 9 | 7 | I | 42 | 1.1 | |
6 | 59 | M | III | LAD, CX, RCA | 4 | 26 | 2.4 | 15 | 15 | 7 | I | 56 | 1.5 | |
7 | 66 | M | IV | LAD, CX, RCA | 2 | 21 | 2.5 | 11 | 11 | 4 | II | 32 | 1.5 | |
8 | 50 | M | III | LAD, CX, RCA | 3 | 37 | 2.3 | 10 | 6 | 4 | I | 38 | 2.0 | |
9 | 50 | M | IV | LAD, CX, RCA | 3 | 30 | 2.2 | 13 | 13 | 9 | II | 41 | 1.6 | |
10 | 68 | M | III | LAD, CX, RCA | 3 | 15 | 2.2 | 7 | 7 | 5 | I | 21 | 1.6 | |
11 | 50 | M | III | LAD, CX, RCA | 2 | 21 | 2.1 | 13 | 13 | 7 | II | 23 | 1.9 | |
12 | 68 | M | III1-150 | LAD, CX, RCA | 4 | 25 | 2.6 | 9 | 4 | 4 | II | 18 | 2.5 | |
13 | 48 | M | IV | LAD, CX, RCA | 3 | 19 | 2.1 | 10 | 9 | 4 | II | 25 | 1.9 | |
14 | 65 | F | III | LAD, CX, RCA | 3 | 37 | 1.6 | 9 | 8 | 3 | II | 40 | 1.4 | |
15 | 63 | M | III | LAD, CX | 3 | 20 | 2.3 | 12 | 12 | 6 | I | 28 | 1.5 | |
16 | 57 | M | III | LAD, CX, RCA | 3 | 22 | 2.6 | 14 | 13 | 11 | I | 37 | 1.6 | |
17 | 66 | M | III | LAD, CX, RCA | 4 | 21 | 2.0 | 7 | 7 | 5 | II | 25 | 1.4 | |
18 | 72 | F | III | LAD, CX, RCA | 3 | 19 | 2.6 | 15 | 15 | 8 | II | 26 | 1.9 | |
19 | 57 | M | III | LAD, CX | 1 | 25 | 2.3 | 14 | 14 | 3 | II | – | 2.1 | |
20 | 62 | M | IV | LAD, CX, RCA | 3 | 10 | 2.5 | 13 | 13 | 4 | I | 29 | 1.9 | |
21 | 66 | M | III | LAD, CX, RCA | 4 | 22 | 2.7 | 15 | 15 | 10 | I | 36 | 1.5 | |
22 | 60 | M | III | LAD, CX, RCA | 5 | 18 | 2.4 | 15 | 12 | 4 | II | 24 | 2.0 | |
23 | 55 | F | III1-150 | LAD, CX, RCA | 4 | 27 | 1.7 | 10 | 10 | 7 | II | 29 | 1.8 | |
24 | 59 | M | III | LAD, CX | 3 | 26 | 2.5 | 15 | 14 | 10 | I | 38 | 1.5 | |
25 | 59 | M | III | LAD, CX, RCA | 4 | 25 | 2.0 | 9 | 8 | 3 | I | 39 | 1.7 | |
26 | 53 | M | III1-150 | LAD, CX, RCA | 2 | 35 | 1.8 | 4 | 0 | 0 | I | 35 | 1.8 | |
27 | 65 | M | III1-150 | LAD, CX, RCA | 3 | 23 | 2.2 | 12 | 0 | 2 | II | 22 | 2.2 | |
28 | 63 | M | III1-150 | LAD, CX, RCA | 3 | 20 | 2.1 | 10 | 10 | 6 | I | 25 | 1.6 | |
29 | 48 | M | III1-150 | LAD, CX, RCA | 4 | 32 | 1.9 | 7 | 4 | 0 | I | 33 | 1.9 | |
30 | 49 | M | III1-150 | LAD, CX | 4 | 35 | 1.8 | 7 | 3 | 1 | I | 36 | 1.8 |
↵1-150 Patient had angina symptoms.
NYHA, New York Heart Association functional class; CAD, coronary artery disease (> 70% stenosis); LAD, left anterior descending; CX, circumflex; RCA, right coronary artery; CABG, coronary artery bypass grafting including branches of main epicardial vessels; EF, left ventricular ejection fraction; WMSI, wall motion score index; DS, dysfunctional left ventricular segments.